Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. (September 2006). "Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials". Lancet. 368 (9539): 929–937. doi:10.1016/s0140-6736(06)69373-2. PMID16962882. S2CID6196840.
Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F (April 2009). "Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries". European Urology. 55 (4): 957–967. doi:10.1016/J.Eururo.2009.01.025. PMID19195772.
Modi NB, Dresser M, Desai D, Jazrawi RP (2005). "Dapoxetine for the treatment of premature ejaculation: Lack of interaction with ethanol". Journal of Urology. 173 (4): 239. doi:10.1016/S0022-5347(18)35971-8.
Giuliano F, Clément P (September 2005). "Physiology of ejaculation: emphasis on serotonergic control". European Urology. 48 (3): 408–417. doi:10.1016/j.eururo.2005.05.017. PMID15996810.
Clément P, Bernabé J, Gengo P, Denys P, Laurin M, Alexandre L, Giuliano F (March 2007). "Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine". European Urology. 51 (3): 825–832. doi:10.1016/J.Eururo.2006.10.011. PMID17064843.
McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, et al. (February 2011). "Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials". The Journal of Sexual Medicine. 8 (2): 524–539. doi:10.1111/j.1743-6109.2010.02097.x. PMID21059176.
Dresser M, Lindert K, Lin D, Gidwani S, Gupta SK, Modi NB (2004). "Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers". Clinical Pharmacology & Therapeutics. 75 (2): P32. doi:10.1016/J.Clpt.2003.11.123. S2CID73406239.
Khan A, Khan S, Kolts R, Brown WA (April 2003). "Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports". The American Journal of Psychiatry. 160 (4): 790–792. doi:10.1176/Appi.Ajp.160.4.790. PMID12668373.
Tamam L, Ozpoyraz N (2002). "Selective serotonin reuptake inhibitor discontinuation syndrome: a review". Advances in Therapy. 19 (1): 17–26. doi:10.1007/Bf02850015. PMID12008858. S2CID5563223.
Johnson DP, Sandlow JI (2018). "Medical Non-Endocrine-Targeted Therapies: Ejaculatory Dysfunction and Immunotherapy". Encyclopedia of Reproduction (2nd ed.). pp. 324–327. doi:10.1016/B978-0-12-801238-3.64785-2. ISBN9780128151457.
Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. (September 2006). "Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials". Lancet. 368 (9539): 929–937. doi:10.1016/s0140-6736(06)69373-2. PMID16962882. S2CID6196840.
Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, et al. (July 2004). "AUA guideline on the pharmacologic management of premature ejaculation". The Journal of Urology. 172 (1): 290–294. doi:10.1097/01.ju.0000132159.61156.ea. PMID15201797.
Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F (April 2009). "Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries". European Urology. 55 (4): 957–967. doi:10.1016/J.Eururo.2009.01.025. PMID19195772.
Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F (2001). "Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction". The Journal of Clinical Psychiatry. 62 (Suppl 3): 10–21. PMID11229449.
Giuliano F, Clément P (September 2005). "Physiology of ejaculation: emphasis on serotonergic control". European Urology. 48 (3): 408–417. doi:10.1016/j.eururo.2005.05.017. PMID15996810.
Clément P, Bernabé J, Gengo P, Denys P, Laurin M, Alexandre L, Giuliano F (March 2007). "Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine". European Urology. 51 (3): 825–832. doi:10.1016/J.Eururo.2006.10.011. PMID17064843.
McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, et al. (February 2011). "Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials". The Journal of Sexual Medicine. 8 (2): 524–539. doi:10.1111/j.1743-6109.2010.02097.x. PMID21059176.
Khan A, Khan S, Kolts R, Brown WA (April 2003). "Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports". The American Journal of Psychiatry. 160 (4): 790–792. doi:10.1176/Appi.Ajp.160.4.790. PMID12668373.
Tamam L, Ozpoyraz N (2002). "Selective serotonin reuptake inhibitor discontinuation syndrome: a review". Advances in Therapy. 19 (1): 17–26. doi:10.1007/Bf02850015. PMID12008858. S2CID5563223.
Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. (September 2006). "Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials". Lancet. 368 (9539): 929–937. doi:10.1016/s0140-6736(06)69373-2. PMID16962882. S2CID6196840.
Dresser M, Lindert K, Lin D, Gidwani S, Gupta SK, Modi NB (2004). "Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers". Clinical Pharmacology & Therapeutics. 75 (2): P32. doi:10.1016/J.Clpt.2003.11.123. S2CID73406239.
Tamam L, Ozpoyraz N (2002). "Selective serotonin reuptake inhibitor discontinuation syndrome: a review". Advances in Therapy. 19 (1): 17–26. doi:10.1007/Bf02850015. PMID12008858. S2CID5563223.
